A transgenic mouse with β-Galactosidase as a fetal liver self-antigen for immunotherapy studies

Journal of Hepatology

Volumn 47, Issue 3, 2007, Pages 396-403

  Cany, Jeannette ^a,b   Avril, Audrey ^a,b   Pichard, Virginie ^a,b   Aubert, Dominique ^a,b   Ferry, Nicolas ^a,b   Conchon, Sophie ^a,b  

^a HÔTEL DIEU   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

Galactosidase; Adenovirus; Alpha fetoprotein; Hepatocellular carcinoma; Immunotherapy; Tolerance

Indexed keywords

ALPHA FETOPROTEIN; BETA GALACTOSIDASE; GAMMA INTERFERON; PLASMID DNA;

ADENOVIRUS; ALPHA FETOPROTEIN PROMOTER GENE; ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; VACCINATION;

ADENOVIRIDAE; AGING; ALPHA-FETOPROTEINS; ANIMALS; ANTIBODY FORMATION; AUTOANTIGENS; BETA-GALACTOSIDASE; CD8-POSITIVE T-LYMPHOCYTES; DNA; FETUS; GENETIC VECTORS; HEPATOCYTES; IMMUNIZATION; IMMUNOTHERAPY; LIVER; MICE; MICE, TRANSGENIC; PLASMIDS; PROMOTER REGIONS (GENETICS);

EID: 34547564106     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.03.018     Document Type: Article

References (36)

1. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 (2004) 909-915
2. Butterfield L.H., Koh A., Meng W., Vollmer C.M., Ribas A., Dissette V., et al. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res 59 (1999) 3134-3142
3. Meng W.S., Butterfield L.H., Ribas A., Heller J.B., Dissette V.B., Glaspy J.A., et al. Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein. Mol Immunol 37 (2000) 943-950
4. Hanke P., Rabe C., Serwe M., Bohm S., Pagenstecher C., Sauerbruch T., et al. Cirrhotic patients with or without hepatocellular carcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human alpha-fetoprotein. Scand J Gastroenterol 37 (2002) 949-955
5. Hanke P., Serwe M., Dombrowski F., Sauerbruch T., and Caselmann W.H. DNA vaccination with AFP-encoding plasmid DNA prevents growth of subcutaneous AFP-expressing tumors and does not interfere with liver regeneration in mice. Cancer Gene Ther 9 (2002) 346-355
6. Meng W.S., Butterfield L.H., Ribas A., Dissette V.B., Heller J.B., Miranda G.A., et al. Alpha-fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 61 (2001) 8782-8786
7. Grimm C.F., Ortmann D., Mohr L., Michalak S., Krohne T.U., Meckel S., et al. Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology 119 (2000) 1104-1112
8. Wang M., Bronte V., Chen P.W., Gritz L., Panicali D., Rosenberg S.A., et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 154 (1995) 4685-4692
9. Chen P.W., Wang M., Bronte V., Zhai Y., Rosenberg S.A., and Restifo N.P. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 156 (1996) 224-231
10. Morgan D.J., Kreuwel H.T., and Sherman L.A. Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. J Immunol 163 (1999) 723-727
11. Krebs P., Scandella E., Odermatt B., and Ludewig B. Rapid functional exhaustion and deletion of CTL following immunization with recombinant adenovirus. J Immunol 174 (2005) 4559-4566
12. Oukka M., Colucci-Guyon E., Tran P.L., Cohen-Tannoudji M., Babinet C., Lotteau V., et al. CD4 T cell tolerance to nuclear proteins induced by medullary thymic epithelium. Immunity 4 (1996) 545-553
13. Overwijk W.W., Surman D.R., Tsung K., and Restifo N.P. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods 12 (1997) 117-123
14. Cosset F.L., Takeuchi Y., Battini J.L., Weiss R.A., and Collins M.K. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J Virol 69 (1995) 7430-7436
15. Arbuthnot P.B., Bralet M.P., Le Jossic C., Dedieu J.F., Perricaudet M., Brechot C., et al. In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector. Hum Gene Ther 7 (1996) 1503-1514
16. Arbuthnot P., Bralet M.P., Thomassin H., Danan J.L., Brechot C., and Ferry N. Hepatoma cell-specific expression of a retrovirally transferred gene is achieved by alpha-fetoprotein but not insulinlike growth factor II regulatory sequences. Hepatology 22 (1995) 1788-1796
17. Higgins G., and Anderson R. Experimental pathology of the liver: restoration of the liver of the white rat following partial surgical removal. Arch Pathol 12 (1931) 186-202
18. Pichard V., Bellodi-Privato M., Gournay J., and Ferry N. Mixed hematopoietic molecular chimerism results in permanent transgene expression from retrovirally transduced hepatocytes in mice. J Gene Med 8 (2006) 425-432
19. Bralet M.P., Pichard V., and Ferry N. Demonstration of direct lineage between hepatocytes and hepatocellular carcinoma in diethylnitrosamine-treated rats. Hepatology 36 (2002) 623-630
20. Zhu L.J., and Altmann S.W. mRNA and 18S-RNA coapplication-reverse transcription for quantitative gene expression analysis. Anal Biochem 345 (2005) 102-109
21. Oukka M., Cohen-Tannoudji M., Tanaka Y., Babinet C., and Kosmatopoulos K. Medullary thymic epithelial cells induce tolerance to intracellular proteins. J Immunol 156 (1996) 968-975
22. Aubert D., Menoret S., Chiari E., Pichard V., Durand S., Tesson L., et al. Cytotoxic immune response blunts long-term transgene expression after efficient retroviral-mediated hepatic gene transfer in rat. Mol Ther 5 (2002) 388-396
23. Butterfield L.H. Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology 127 (2004) S232-S241
24. Butterfield L.H., Ribas A., Dissette V.B., Lee Y., Yang J.Q., De la Rocha P., et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 12 (2006) 2817-2825
25. Cailliau K., Bois-Joyeux B., and Danan J.L. Rat alpha-fetoprotein promoter and proximal enhancer direct expression of the nls-lacZ reporter gene in embryonic yolk sac, gut, and eustachian canal of transgenic mice. Tumour Biol 21 (2000) 278-287
26. Tilghman S.M., and Belayew A. Transcriptional control of the murine albumin/alpha-fetoprotein locus during development. Proc Natl Acad Sci USA 79 (1982) 5254-5257
27. Vollmer Jr. C.M., Eilber F.C., Butterfield L.H., Ribas A., Dissette V.B., Koh A., et al. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 59 (1999) 3064-3067
28. Overwijk W.W. Breaking tolerance in cancer immunotherapy: time to ACT. Curr Opin Immunol 17 (2005) 187-194
29. Bowen D.G., McCaughan G.W., and Bertolino P. Intrahepatic immunity: a tale of two sites?. Trends Immunol 26 (2005) 512-517
30. Blankenstein T. The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 17 (2005) 180-186
31. Koen H., Pugh T.D., Nychka D., and Goldfarb S. Presence of alpha-fetoprotein-positive cells in hepatocellular foci and microcarcinomas induced by single injections of diethylnitrosamine in infant mice. Cancer Res 43 (1983) 702-708
32. Schmitz V., Tirado-Ledo L., Tiemann K., Raskopf E., Heinicke T., Ziske C., et al. Establishment of an orthotopic tumour model for hepatocellular carcinoma and non-invasive in vivo tumour imaging by high resolution ultrasound in mice. J Hepatol 40 (2004) 787-791
33. Thomas C.E., Ehrhardt A., and Kay M.A. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4 (2003) 346-358
34. Jager E., Karbach J., Gnjatic S., Neumann A., Bender A., Valmori D., et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA 103 (2006) 14453-14458
35. Dullaers M., Van Meirvenne S., Heirman C., Straetman L., Bonehill A., Aerts J.L., et al. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther 13 (2006) 630-640
36. Mohr A., Henderson G., Dudus L., Herr I., Kuerschner T., Debatin K.M., et al. AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression. Gene Ther 11 (2004) 534-543